In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Quiz|Articles|September 27, 2026
Dermatology Times Spot Test: September 27, 2026
Author(s)Shannon Heaning, Content Associate
Listen
0:00 / 0:00
Key Takeaways
- Weekly spot-test format aims to reinforce dermatology fundamentals while integrating evolving evidence and practice patterns.
- This installment concentrates on hidradenitis suppurativa treatment frameworks, including medical, procedural, and emerging approaches.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on hidradenitis suppurativa (HS) management, including biologic treatment, deroofing, and emerging strategies discussed by Alexandra Charrow, MD, FAAD, at Maui Derm NP+PA Fall 2026.
Do you have a set of quiz questions to share? Contact editor Shannon Heaning at Sheaning
According to Alexandra Charrow, MD, FAAD, which clinical findings can help clinicians assess the inflammatory burden of hidradenitis suppurativa when considering escalation to biologic therapy?
What procedural intervention did Charrow encourage dermatology clinicians to become more comfortable incorporating into hidradenitis suppurativa care?
What emerging area of research did Charrow identify as potentially helping clinicians select the most appropriate hidradenitis suppurativa therapy for individual patients?
Advertisement
Related to this article
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5